Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Vistagen Therapeutics Inc VTGN

Healthcare Biotechnology
Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company focuses on transforming the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. It is advancing therapeutics for treatment of anxiety, depression, and multiple CNS disorders. Its pipeline includes six clinical-stage product candidates... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:VTGN)

Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference

Business Wire April 9, 2024

Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2

Business Wire April 1, 2024

Vistagen to Present at Stifel 2024 Virtual CNS Days

Business Wire March 11, 2024

Vistagen to Present at TD Cowen 44th Annual Health Care Conference

Business Wire February 28, 2024

Vistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate Update

Business Wire February 13, 2024

Vistagen to Report Fiscal Year 2024 Third Quarter Financial Results and Host Corporate Update Conference Call on February 13, 2024

Business Wire February 6, 2024

Vistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Pain

Business Wire December 27, 2023

Vistagen Provides Corporate Update and Reports Fiscal 2024 Second Quarter Financial Results

Business Wire November 9, 2023

Vistagen to Present at Stifel 2023 Healthcare Conference

Business Wire November 8, 2023
View More News ››

Opinion & Analysis (NDAQ:VTGN)

VistaGen's fast-acting antidepressant targets multibillion-dollar market

The Life Sciences Report April 27, 2017

VistaGen Therapeutics advances new-generation antidepressant approved by European Patent Office

The Life Sciences Report April 6, 2017

VistaGen licenses stem cell technology to new firm backed by big pharma

The Life Sciences Report December 23, 2016

How markets are rigged against you

Stockhouse Editorial April 14, 2014
View More Opinion ››

Bullboard Posts (NDAQ:VTGN)

VSTA - Friday Rundown, Monday Expectations

<< View Post To Watch Video >>
HDavis - December 10, 2021

RE:RE:VTGN - Flying with out any news

Yes a lot of volatility right now. Can be good to avoid this stock for now. Depression stocks will soon be out of favour, when the Covid...
canarsta - January 26, 2021

RE:VTGN - Flying with out any news

Take a look on Twitter, lots of hyping. 
Commoncents - January 25, 2021

VTGN - Flying with out any news

Something is brewing. It is lok down time and it keeps secure the money.
MoneyStock - December 16, 2020

VTGN - Another news out.

VistaGen Announces Korean Intellectual Property Office Decision to Grant PH10 Patent for Treatment of Depression ...
HugeMoney - December 10, 2020

VTGN- News Out

SO PAULO, Brazil, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Vasta Platform Limited (NASDAQ: VSTA) announces the acquisition of Meritt...
HugeMoney - December 10, 2020
View more Bullboard ››

Strategic Resources Inc.

Strategic Resources Inc.

Strategic Resources is a Canada based development company focused on vanadium, high purity iron & titanium, metals necessary ...
View More »